Tharimmune, Inc. THAR

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
9/100
Weak

About Tharimmune, Inc.

Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was founded in 2017 … Full THAR analysis →

Competitive advantage assessment

Key risks

  • ROIC Below WACC or Peers ROIC at 2.2th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.14), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—

Where THAR ranks in Biotechnology

Tharimmune, Inc. ranks #646 of 713 scored companies in Biotechnology by moat score — the top 91%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near THAR in Biotechnology
# Company Moat score Rating
642 Cingulate Inc. Warrants CINGW 12/100 Weak
643 Inovio Pharmaceuticals, Inc. INO 11/100 Weak
644 Aditxt, Inc. ADTX 11/100 Weak
645 CNS Pharmaceuticals, Inc. CNSP 10/100 Weak
646 Tharimmune, Inc. THAR 9/100 Weak
647 FibroBiologics, Inc. FBLG 9/100 Weak
648 Tiziana Life Sciences Ltd TLSA 9/100 Weak
649 MAIA Biotechnology, Inc. MAIA 7/100 Weak
650 Alzamend Neuro, Inc. ALZN 6/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How THAR scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 5 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 15 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding THAR's moat

What is Tharimmune, Inc.'s moat score?

Tharimmune, Inc. (THAR) scores 9 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #646 of 713 scored companies in Biotechnology, the top 91%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (15/100) and its weakest is Capital Efficiency (5/100).

How does Tharimmune, Inc. compare with other Biotechnology companies?

Tharimmune, Inc. ranks #646 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are CNS Pharmaceuticals, Inc. (CNSP) at 10 just above it and FibroBiologics, Inc. (FBLG) at 9 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Tharimmune, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Tharimmune, Inc.?

The Corporate Default template measures 6 defenses, and THAR scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (5), Resilience (15), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000